OriGene Technologies

OriGene Technologies

Sells gene-based research tools and reagents

Overview

OriGene Technologies provides gene-based research tools and reagents for academic, pharmaceutical, and biotech researchers. It sells cDNA clones, antibodies, proteins, RNAi, and lentiviral particles directly to research institutions worldwide. It differentiates itself with a very large inventory and a distributed manufacturing network that enables rapid access to a broad set of gene-based tools. Its goal is to help researchers advance gene-based science by providing reliable reagents and educational resources.

About OriGene Technologies

Simplify's Rating
Why OriGene Technologies is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Biotechnology

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$69.4M

Headquarters

Rockville, Maryland

Founded

1996

Get referred to OriGene Technologies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • March 2026 launch added ultracentrifuge-free EV isolation and CD9 ELISA kits.
  • OriGene's April and May 2026 conference schedule signals active product commercialization.
  • Podcast additions in 2026 keep OriGene embedded in high-impact publications and citations.

What critics are saying

  • Zhongyuan Union's 2017 ownership keeps OriGene exposed to U.S.-China procurement scrutiny.
  • Thermo Fisher, Abcam, and Bio-Techne crowd validated-antibody pricing, squeezing margins by 2027.
  • A U.S. campus boycott of China-owned suppliers guts North American demand.

What makes OriGene Technologies unique

  • OriGene's 17K protein chip underpins UltraMAB and KO validation, differentiating antibody specificity.
  • May 2026 KD-Validated Antibodies page showcases IDH1, EGFR, and UCHL1 knockdown-validated reagents.
  • April 2026 EV kits bundle CD9 and CD81 capture around validated magnetic beads.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$69.4M

Below

Industry Average

Funded Over

4 Rounds

Notable Investors:
Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison
Coming Soon

Benefits

Mentorship Program

Professional Development Budget

Conference Attendance Budget

Training Programs

Professional Certification Support

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
OriGene Technologies Inc.
Nov 9th, 2023
CytoSections™ - Use case for antibody validation of the IDH1(R132H) mutation in Glioblastomas

OriGene has developed a tool for antibody validation called CytoSections.

Recently Posted Jobs

Sign up to get curated job recommendations

OriGene Technologies is Hiring for 5 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →